Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar… - The Lancet, 2018 - thelancet.com
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

S Tiberi, N du Plessis, G Walzl, MJ Vjecha… - The Lancet Infectious …, 2018 - thelancet.com
Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

Tuberculosis and COVID-19 co-infection: description of the global cohort

TB/COVID-19 Global Study Group - European Respiratory …, 2022 - Eur Respiratory Soc
Background Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is
still limited. The aim of this study was to describe the features of the TB/COVID-19 co …

Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline

P Nahid, SR Mase, GB Migliori, G Sotgiu… - American journal of …, 2019 - atsjournals.org
Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Z Lan, N Ahmad, P Baghaei, L Barkane… - The Lancet …, 2020 - thelancet.com
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis

P Miotto, B Tessema, E Tagliani… - European …, 2017 - Eur Respiratory Soc
A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing …

Drug‐resistant tuberculosis: an update on disease burden, diagnosis and treatment

C Lange, D Chesov, J Heyckendorf, CC Leung… - …, 2018 - Wiley Online Library
The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a …

NA Ismail, SV Omar, H Moultrie, Z Bhyat… - The Lancet Infectious …, 2022 - thelancet.com
Background Bedaquiline improves outcomes of patients with rifampicin-resistant and
multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this …

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in …

N Ndjeka, JR Campbell, G Meintjes… - The Lancet Infectious …, 2022 - thelancet.com
Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

S Borisov, E Danila, A Maryandyshev… - European …, 2019 - Eur Respiratory Soc
The World Health Organization (WHO) recommends that countries implement
pharmacovigilance and collect information on active drug safety monitoring (aDSM) and …